4320 Forest Park Avenue
Immunophotonics is a biotech company developing a proprietary drug for use in a therapeutic cancer vaccine (inCVAX). This novel immunotherapy begins with a two injection procedure into any one accessible tumor, intended to liberate and utilize the patient’s tumor antigens to generate a systemic antitumor immune response.
Founder and CEO: Tomas Hode, PhD
COO Lu Alleruzzo, MBA
CDO (Chief Drug Dev. Officer): Joe Raker, PhD